Molecular Targeting Technologies

Healthtech

Overview

Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company primarily focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases. MTTI has licensed and is developing two major technology platforms to provide: (i) novel small molecule drug conjugate (SMDC) cancer therapeutic, and (ii) in vivo imaging agents. 

Founder(s)

Chris Yan

Contact

Chris Yan
Visit Molecular Targeting Technologies website